GlassScriptPhysician profile
Jean A Christ
NPI 1679947055
$6,318.12
in general payments reported to CMS, 2019-2025
33 companies · $775 in 2025
The $775 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,932 · 2022: $1,253 · 2023: $1,222 · 2024: $1,137 · 2025: $775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,133.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,267.52 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,119.85 | 2021-2025 | Mounjaro, Trulicity, Zepbound |
| Novo Nordisk INC | $759.71 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $491.34 | 2021-2023 | Xarelto |
| Abbvie INC. | $479.86 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $264.91 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $184.79 | 2021-2025 | Xifaxan |
| Astellas Pharma US INC | $174.67 | 2021-2025 | Veozah |
| Amarin Pharma, INC. | $145.73 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $145.34 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.07 | 2021-2025 | Jardiance |
| Lundbeck LLC | $125.38 | 2021-2025 | Rexulti |
| Glaxosmithkline, LLC. | $97.09 | 2021 | |
| Merck Sharp & Dohme LLC | $95.42 | 2021-2022 | |
| Abbott Laboratories | $92.70 | 2021-2024 | Freestyle Libre |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $87.63 | 2023-2025 | Auvelity |
| Biohaven Pharmaceuticals, INC. | $75.79 | 2021 | |
| Sanofi-Aventis U.S. LLC | $68.01 | 2021-2023 | |
| Vanda Pharmaceuticals INC. | $66.78 | 2024 | Fanapt, Hetlioz |
| Amgen INC. | $65.88 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $53.97 | 2021-2022 | |
| Pfizer INC. | $53.55 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $52.67 | 2021 | |
| Organon LLC | $36.78 | 2021-2025 | Nexplanon |
| Takeda Pharmaceuticals U.S.A., INC. | $35.24 | 2021-2024 | Trintellix |
| Genentech USA, INC. | $28.93 | 2021-2022 | |
| Genzyme Corporation | $20.58 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.67 | 2022 | |
| Dexcom, INC. | $15.38 | 2021 | |
| Mylan Specialty L.P. | $14.05 | 2023 | Yupelri |
| Biohaven Pharmaceutical Holding Company LTD. | $13.69 | 2022 | |
| Jazz Pharmaceuticals INC. | $13.37 | 2021 | |
| Exact Sciences Corporation | $12.77 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean Christ listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.